Manufacturer
ALLERGAN PHARMACEUTICALS IRELAND
Contents
Prednisolone acetate
Indication
Ophthalmic Inflammatory eye disorders.
Instruction
Instill 1-2 drops into the conjunctival sac 2-4 times/day, may increase to 2 drops hourly during the initial 24-48 hours
Drug interaction
Increased systemic adverse effects with CYP3A inhibitors, including. cobicistat-containing products. Increased metabolism rate with CYP3A4 inducers (e.g. phenobarbital, rifampicin, primidone, aminoglutethimide) resulting to reduced therapeutic efficacy. Decreased clearance with CYP3A4 inhibitors (e.g. ketoconazole, troleandomycin). Antagonistic effect with hypoglycaemic agents (e.g. insulin), antihypertensives and diuretics. Enhances hypokalaemic effect of diuretics (e.g. acetazolamide), carbenoxolone, theophylline and sympathomimetic agents (e.g. salbutamol, terbutaline). Increased GI ulceration with concomitant use of ulcerogenic drugs (e.g. indomethacin). Increases renal clearance of salicylates, abrupt corticosteroids withdrawal may result in salicylate intoxication. Oestrogens may potentiate the effect of prednisolone. Reduced effect with mifepristone. Enhances efficacy of anticoagulants which may result to spontaneous bleeding. May antagonise the hypoglycaemic effect of antidiabetics. Decreased plasma clearance with ciclosporin.
Potentially Fatal: Diminishes antibody response to live vaccines due to impaired immune system.
Malaysia
